TD has acquired Cowen Inc. Please bookmark TD Securities for further updates.

$85 Million

Evelo Biosciences

Initial Public Offering

Bookrunner, May 2018

Evelo Biosciences
Evelo Biosciences is pioneering the development of therapies designed to act on the gut-body network. The Company is developing orally-delivered pharmaceutical compositions of naturally occurring specific microbial strains.